Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study

Open access
Ruiz-Moreno, José M., Arias, Luís, Abraldes, Maximino J., Montero, Javier, Udaondo, Patricia, The RAMDEBURS study group·2021·International Ophthalmology

Abstract

Purpose: To describe and evaluate the main direct health costs, in routine clinical practice, of age-related macular degeneration (AMD) patients, from hospital perspective, in Spain. Methods: Retrospective, multicenter, and observational study conducted on five third-level Spanish hospitals, between December 2018 and December 2019. The study included patients who were diagnosed of AMD before December 2018. Direct healthcare costs were obtained from a Spanish database. Study variables included demographic and clinical variables, and resources, such as treatment, diagnostic tests, medical examination, and surgery. Among the 1414 screened AMD patients, 1164 patients were included. In the overall study patients, the total cost was €5,386,511.0, with a mean cost per patient of €4627.6 ± 2383.9. The largest cost items were diagnostic examinations (€2.832.902,0) and vascular endothelial growth factor inhibitors (anti-VEGF) treatment (€2.038.257,2). Bevacizumab was administered to 325 (27.9%) patients, ranibizumab to 328 (28.2%), and aflibercept to 626 (53.8%); 115 (10.7%) patients received two anti-VEGF treatments, while 90 (7.7%) did not receive any. Over the course of the study, a total of 6,057 anti-VEGF injections were administered, with a mean (95% confidence interval) of 4.8 (4.4–5.2) injections per patient. Regarding safety, 29 patients experience injection-related adverse events, among them 12 patients had cataract and 11 ones elevated intraocular pressure (IOP). The incidence of endophthalmitis was 0.5% (6/1164). Conclusions: AMD was associated with considerable healthcare costs for regional healthcare systems. Diagnostic examinations, particularly OCT examinations, and anti-VEGF treatment represented the largest cost items.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10792-021-01906-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study flowchart
Fig. 1 Study flowchartCC BY · PubMed Central
Fig. 2 Number of intravitreal injections according to the vascular endothelial growth factor inhibitor administered
Fig. 2 Number of intravitreal injections according to the vascular endothelial growth factor inhibitor administeredCC BY · PubMed Central
Fig. 3 Overview of costs distribution among the different items (%)
Fig. 3 Overview of costs distribution among the different items (%)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 43

Metadata

Authors
Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & The RAMDEBURS study group
Affiliations
  • Bellvitge University Hospital (ES)
  • Complejo Hospitalario Universitario de Santiago (ES)
  • Hospital Universitario Río Hortega (ES)
  • Hospital Universitari i Politècnic La Fe (ES)
Venue
International Ophthalmology
Published
2021-06-10
Volume
41
Issue
10
Pages
3427-3436
ISSN
  • 0165-5701 (ISSN-L)
  • 1573-2630
OpenAlex
W3170401063
Cited by
41
References
34
Citations by year
2026: 6 · 2025: 12 · 2024: 14 · 2023: 5 · 2022: 2 · 2021: 2
FWCI
5.16
Type
journal article
Language
en
Open access
Licence
Locations
  • International Ophthalmology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
Funders
Allergan
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
age-related macular degeneration, economic burden, health care costs, anti-VEGF therapy, bevacizumab, ranibizumab, aflibercept, optical coherence tomography, endophthalmitis, cataract, intraocular pressure, hospital costs
MeSH terms
Bevacizumab, Ranibizumab, Humans, Macular Degeneration, Recombinant Fusion Proteins, Retrospective Studies, Visual Acuity, Cost of Illness, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. https://app.cochat.ai/papers/10.1007/s10792-021-01906-x
The paper
Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & The RAMDEBURS study group. (2021). Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. International Ophthalmology. https://doi.org/10.1007/s10792-021-01906-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.